Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
Jennifer Wilkinson CarlisleCaroline S JansenMaria Andrea CardenasEwelina SobierajskaAdriana Moon ReyesRachel GreenwaldLuke Del BalzoNataliya ProkhnevskaOmer KucukBradley C CarthonPatrick Connor MullaneAdeboye OsunkoyaDeborah BaumgartenFares HosseinzadehScott WilkinsonRoss LakeAdam G SowalskyYuan LiuViraj A MasterMehmet Asim BilenHaydn T KissickPublished in: Journal for immunotherapy of cancer (2022)
Together, these data suggest that having a strong pre-existing immune response and immediate peripheral T-cell activation after checkpoint therapy is a predictor of clinical benefit in patients with RCC.